promis neurosciences stock price prediction today

``` The deep research logic is organized as follows: Okay, let's tackle this question about ProMIS Neurosciences' stock price prediction for today, July 22, 2025. First, I need to check the references provided. Looking at the references, there's a query result for PMN's stock price forecast on July 22, 2025. The data shows the last price as $1.12 with a 154.49% change, and the forecast price is $0.94 . That's a significant drop from the last price. Hmm, that's interesting. Also, another query about the latest financial estimates mentions the same date, with the closing price at $1.12 and an estimated EPS of -0.15 . Wait, the stock surged after the FDA Fast Track designation on July 21, 2025. The articles mention shares more than doubling to $1.19 , and premarket surges of 17.50% and 21.37% . But the forecast for today is lower than the closing price yesterday. That might be due to market reactions or adjustments after the news. Also, the earnings release date is August 14, 2025 , which is after today. So, no earnings impact yet. The company's market cap is $14.4 million , which is quite small, making the stock more volatile. The user is asking for today's prediction. The forecast from the query is $0.94, which is lower than the last price of $1.12. But the stock surged yesterday, so maybe the market is adjusting. However, the forecast might be based on technical analysis or models that predict a pullback after the surge. I should also consider the lack of analyst estimates for today and , which means there's no consensus from analysts, possibly due to the recent news. The company's financial health is concerning with a negative EPS estimate , indicating losses. Putting this together, the forecast suggests a drop from the previous day's surge, but the stock is still in a bullish phase due to the FDA news. The market might be consolidating after the big move. The user should be aware of the volatility and the upcoming earnings in August. I need to present this clearly, starting with the conclusion, then the analysis, and include the table from the query. Also, add the visualization as per the requirements. Make sure to cite the references properly and keep the language professional yet engaging. ``` **Conclusion** 🎯 ProMIS Neurosciences (PMN) stock is expected to experience volatility today, July 22, 2025, following its recent surge after the FDA Fast Track designation for its Alzheimer’s treatment candidate, PMN310. Based on the latest data, the forecasted price for today is **$0.94**, reflecting a potential pullback from yesterday’s surge . However, the stock remains in a bullish trajectory due to its clinical-stage advancements and regulatory momentum. --- ### 📊 **Stock Price Analysis** Here’s a breakdown of the key data points: | Metric | Value (as of July 22, 2025) | Context/Implications | |----------------------------|-------------------------------|---------------------------------------------------------------------------------------| | **Last Price** | $1.12 | Surged 154.49% yesterday after FDA news . | | **Forecast Price** | $0.94 | Predicted drop from yesterday’s high, likely due to profit-taking or market consolidation . | | **Earnings Release Date** | August 14, 2025 | No immediate earnings impact; focus remains on clinical trials and regulatory updates . | | **Market Cap** | $14.4M | Small-cap biotech with high volatility and speculative risk . | | **EPS Estimate** | -$0.15 | Ongoing losses highlight early-stage development risks . | --- ### 🌟 **Key Takeaways** 1. **FDA Catalyst**: The Fast Track designation for PMN310 is a major driver of recent momentum. The drug targets toxic oligomers in Alzheimer’s, offering a differentiated approach to reduce side effects like brain swelling . 2. **Clinical Trials**: The PRECISE-AD Phase 1b trial is evaluating safety and efficacy, with interim data expected in Q2 2026 . 3. **Risks**: High volatility, negative EPS, and a small market cap make PMN a high-risk, high-reward play. --- --- ### 🎯 **Final Outlook** ProMIS Neurosciences is positioned for long-term upside if PMN310 demonstrates safety and efficacy in trials. However, short-term volatility is likely as the market digests the FDA news and awaits clinical updates. Stay vigilant for updates on the Phase 1b trial and potential partnerships.